Physician profile
Clair A Travis
NPI 1609137983
$4,790.92
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,929 · 2022: $2,160 · 2023: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $743.36 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $575.22 | 2021-2023 | Stiolto Respimat, Spiriva Respimat, Synjardy |
| Novo Nordisk INC | $507.48 | 2021-2023 | Wegovy |
| Pfizer INC. | $421.90 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $394.40 | 2021-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $385.17 | 2021-2023 | Mounjaro |
| Amgen INC. | $230.10 | 2021-2023 | Prolia, Evenity |
| Astellas Pharma US INC | $155.74 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $148.17 | 2021-2023 | Airduo Digihaler |
| Bayer Healthcare Pharmaceuticals INC. | $135.73 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.43 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $119.50 | 2021-2023 | Seglentis, Livalo |
| Janssen Pharmaceuticals, INC | $94.19 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $92.41 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $90.84 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $73.28 | 2021-2022 | |
| Axsome Therapeutics, INC. | $69.41 | 2022-2023 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $63.87 | 2021 | |
| Paratek Pharmaceuticals, INC. | $55.39 | 2022 | |
| Merck Sharp & Dohme LLC | $54.21 | 2022-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Exact Sciences Corporation | $39.87 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $36.91 | 2022-2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $22.91 | 2022 | |
| Vanda Pharmaceuticals INC. | $22.10 | 2021 | |
| Eisai INC. | $20.84 | 2021 | |
| Allergan, INC. | $19.87 | 2021 | |
| Biogen, INC. | $19.16 | 2021 | |
| Philips North America LLC | $18.53 | 2021 | |
| Esperion Therapeutics, INC. | $15.64 | 2021 | |
| Cranial Technologies, INC | $15.10 | 2023 | Doc Band |
| Boston Scientific Corporation | $14.34 | 2022 | |
| Currax Pharmaceuticals LLC | $13.85 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clair Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.